Obama budget targets brand name medicines

February 14, 2011

Big pharmaceutical companies could face increased competition from generic drugmakers under two proposals put forth by the Obama administration on Monday despite earlier savings extracted from drugmakers as part of last year’s healthcare law. Read More

Read More


Biologics Exclusivity Cut Called for in President’s Budget: All Bark, No Bite

February 14, 2011

The Obama Administration’s fiscal 2012 budget document includes a call to reduce innovator biologics exclusivity from the 12 years just enacted as part of the health care reform law to 7 years, a number more in line with the position supported by advocates on the generic/drug/purchaser/consumer side of the debate. Read More

Read More


Next generation biologic drugs provide hope for HIV/AIDS patients

January 26, 2011

James Sykes, Director of Global Policy, The AIDS Institute The Hill Our nation’s political capital, Washington D.C. also has the notorious distinction of being the HIV and AIDS capital of the United States, with at least 3 percent of its residents infected. This rate is higher than most countries in West Africa and exceeds the […]

Read More


The High Cost of Cheaper Drugs

January 26, 2011

Marcia Boyle, President and Founder, Immune Deficiency Foundation AOL News Thirty years ago my infant son was diagnosed with a rare genetic disorder that make even common cold germs potentially life threatening. His disorder — clinically termed a primary immunodeficiency disease — started me on my career as a patient activist. Read More

Read More


Biologic Drugs: Biosimilars May Be Cheaper, But Are They Safe?

December 14, 2010

Where there’s medicine, there’s money.

Read More


European Union provides a good example of effective biosimilars pathway

December 14, 2010

Biologic drugs can treat a variety of illnesses—including cancer and certain types of arthritis—imore effectively than traditional, chemical based products.

Read More


FDA must establish safe approval pathway for biosimilar drugs

December 14, 2010

Biologic drugs are often referred to as ”miracle drugs“ for good reason…

Read More


Proceed with caution on creating ‘biosimilar’ drugs

November 15, 2010

Americans elected a new Congress on Nov. 2, but the voting booth wasn’t the only place where critical issues were at stake that day.

Read More


The new battle over prescription drugs

November 11, 2010

Away from the spotlight of election news coverage, a committee of the U.S. Food and Drug Administration (FDA) held a hearing in a Washington suburb on the future of biologic drugs…

Read More


Biologics: Are Unsafe Drugs an ‘Acceptable Risk?’ FDA Should Say ‘No!’

November 7, 2010

For cancer patients, what is the “acceptable risk” that a drug will pose safety risks or won’t work properly?

Read More